We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go: Expired investment: £5,083,686
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go: Expired investment: £3,768,260
Baanx is a B2B2C mobile banking platform offering cutting-edge services in remittance, spending & blockchain. The company takes pride in its innovative customer acquisition process through partner communities. The BaanxCL already has a CL™ VISA Debit Card, Crypto-Payment Gateway, a Crypto-Exchange, Stablecoins, and other exciting features. The company is also partnering with new brands around the world which are not banking already but have large user communities to connect. The company is aiming to target 100,000 users by Q2 2020 with the assistance of Super Seed Investors. With the proceeds, Baanx will hire additional team members, spend funds on marketing, and launch services in South America and Asia.

Pitch Rated

49%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £658,200
Landbay is a marketplace lender that's main focus is on prime residential mortgages. They match investors' funds directly to loans. Landbay plan to use the proceeds for general working purposes.  
days to go: Expired investment: £1,601,371
Rabble is a gamified and licensed fitness program that transforms exercise into fun, team-based games. It was first formed by a former international athlete and then financed by investors from the LA Fitness & Liverpool football club. Rabble has quickly risen to 100 authorized sites strengthening many healthy communities over the UK. It is a differentiated concept which is named as Global Fitness Trend (WGSN). It has a proven and scalable model where the market leaders earn revenue of more than $100m. Further, it has developed 100+ instructors across the UK in less than one year. Rabble aims at helping and changing more lives with the finance that it raises. It is planning to grow to more than 300 Rabble sites in the coming year.
days to go: Expired investment: £274,530
Juggle helps companies hire, manage and retain experienced professionals on flexible contracts. The company has onboarded more than 9000 professionals and over 700 businesses on its platform. Juggle asserts that its portal is completely free for companies to post jobs wherein professionals will receive a recommendation to the right opportunities based on their profiles. Juggle allows both companies and candidates to manage the timesheet and payment formalities through its platform once a contract is agreed upon. The company claims that 85% of professionals recommended by its platform are interviewed. Juggle aims to become a contender in the online recruitment industry that is projected to reach $36.2 billion by 2027. It will use the investment to make additional hires in certain key positions, expand product features, and apply to the FCA for a license to handle payments at a larger scale.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £467,537
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph